Antiviral Drug Targets and Strategies for Emerging Viral Diseases and Bioterrorism Threats

Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats

Volumn , Issue , 2005, Pages 83-113

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral drugs; Coronavirus; Ebola virus; Hemorrhagic fevers; Influenza; Smallpox

Indexed keywords

EID: 84891005770     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471716715.ch4     Document Type: Chapter

References (87)

1. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 2002, 1, 13-25.
2. Mahy, B. W. J. An overview on the use of a viral pathogen as a bioterrorism agent: why smallpox? Antiviral Res. 2003, 57, 1-5.
3. Baker, R. O.; Bray, M.; Huggins, J. W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003, 57, 13-23.
4. Smee, D. F.; Sidwell, R. W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003, 57, 41-52.
5. Neyts, J.; De Clercq, E. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res. 2003, 57, 25-33.
6. De Clercq, E.; Neyts, J. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev. Med. Virol. 2004, 14, 289-300.
7. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55, 1-13.
8. Neyts, J.; De Clercq, E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 1993, 41, 242-246.
9. Huggins, J. W.; Martinez, M. J.; Hartmann, C. J.; Hensley, L. E.; Jackson, D. L.; Kefauver, D. F.; Kulesh, D. A.; Larsen, T.; Miller, D. M.; Mucker, E. M.; Shamblin, J. D.; Tate, M. K.; Whitehouse, C. A.; Zwiers, S. H; Jahrling, P. B. Successful cidofovir treatment of smallpox-like disease in variola and monkeypox primate models. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A57, no. 76.
10. Evans, D. H.; Magee, W.; Hostetler, K. Y. Inhibition of orthopoxvirus DNA polymerases by cidofovir diphosphate: in vitro enzymatic studies using highly purified vaccinia virus DNA polymerase. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A57, no. 74.
11. Andrei, G.; Holy, A.; Fiten, P.; Opdenakker, G.; De Clercq, E.; Snoeck, R. Isolation of vaccinia virus (VV) mutants resistant to different acyclic nucleoside phosphonate analogues (ANPs). Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A72, no. 111.
12. Smee, D. F.; Bailey, K. W.; Holy, A.; Sidwell, R. W. A cidofovir-resistant form of the highly virulent WR strain of vaccinia virus is cross-resistant to related antiviral agents and is highly attenuated for virulence in mice. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A57, no. 75.
13. Kern, E. R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J. R.; Hostetler, K. Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991-995.
14. 14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 2003, 63, 678-681.
15. Neyts, J.; Leyssen, P.; Verbeken, E.; De Clercq, E. Efficacy of cidofovir in a murine model for disseminated/progressive vaccinia. Antimicrob. Agents Chemother. 2004, 48, 2267-2273.
16. Gritsun, T. S.; Lashkevich, V. A.; Gould, E. A. Tick-borne encephalitis. Antiviral Res. 2003, 57, 129-146.
17. Leyssen, P.; Charlier, N.; Paeshuyse, J.; De Clercq, E.; Neyts, J. Prospects for antiviral therapy. Adv. Virus Res. 2003, 61, 511-553.
18. Leyssen, P.; Croes, R.; Rau, P.; Heiland, S.; Verbeken, E.; Sciot, R.; Paeshuyse, J.; Charlier, N.; De Clercq, E.; Meyding-Lamade, U.; Neyts, J. Acute encephalitis, a poliomyelitis-like syndrome and neurological sequelae in a hamster model for flavivirus infections. Brain Pathol. 2003, 13, 279-290.
19. Leyssen, P.; Drosten, C.; Paning, M.; Charlier, N.; Paeshuyse, J.; De Clercq, E.; Neyts, J. Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob. Agents Chemother. 2003, 47, 777-782.
20. Neyts, J.; Meerbach, A.; McKenna, P.; De Clercq, E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res. 1996, 30, 125-132.
21. Morrey, J. D.; Smee, D. F.; Sidwell, R. W.; Tseng, C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 2002, 55, 107-116.
22. Iversen, P. L.; Stein, D.; Kroeker, A.; Arora, V.; Barklis, E., Hill, A.; Smith, A.; Wallace, R. Rapid development of an antisense phosphorodiamidate morpholino oligomer for the treatment of West Nile virus. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A32, no. 15.
23. Charrel, R. N.; de Lamballerie, X. Arenaviruses other than Lassa virus. Antiviral Res. 2003, 57, 89-100.
24. Drosten, C.; Kümmerer, B. M.; Schmitz, H.; Günther, S. Molecular diagnostics of viral hemorrhagic fevers. Antiviral Res. 2003, 57, 61-87.
25. Andrei, G.; De Clercq, E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res. 1990, 14, 287-300.
26. McCormick, J. B.; King, I. J.; Webb, P. A.; Scribner, C. L.; Craven, R. B.; Johnson, K. M.; Elliott, L. H. Belmont-Williams, R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314, 20-26.
27. Sidwell, R. W.; Smee, D. F. Viruses of the Bunya-and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res. 2003, 57, 101-111.
28. Clement, J. P. Hantavirus. Antiviral Res. 2003, 57, 121-127.
29. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-1998. A 32-year-old woman with pharyngeal spasms and paresthesias after a dog bite. N. Engl. J. Med. 1998, 339, 105-112.
30. Bray, M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003, 57, 53-60.
31. Kuiken, T.; Fouchier, R.; Rimmelzwaan, G.; Osterhaus, A. Emerging viral infections in a rapidly changing world. Curr. Opin. Biotechnol. 2003, 14, 641-646.
32. Walsh, P. D.; Abernethy, K. A.; Bermejo, M.; Beyers, R.; De Wachter, P.; Akou, M. E.; Huijbregts, B.; Mambounga, D. I.; Toham, A. K.; Kilbourn, A. M., Lahm, S. A.; Latour, S.; Maisels, F.; Mbina, C.; Mihindou, Y.; Obiang, S. N.; Effa, E. N.; Starkey, M. P.; Teifer, P.; Thibault, M.; Tutin, C. E. G.; White, L. J. T.; Wilkie, D. S. Catastrophic ape decline in western equatorial Africa. Nature 2003, 422, 611-614.
33. Jahrling, P. B.; Geisbert, T. W.; Geisbert, J. B.; Swearengen, J. R.; Bray, M.; Jaax, N. K.; Huggins, J. W.; LeDuc, J. W.; Peters, C. J. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 1999, 179 (Suppl. 1), S224-S234.
34. De Clercq, E., S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol. 1987, 36, 2567-2575.
35. De Clercq, E.; Cools, M.; Balzarini, J.; Marquez, V. E.; Borcherding, D. R.; Borchardt, R. T.; Drach, J. C.; Kitaoka, S.; Konno, T. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives. Antimicrob. Agents Chemother. 1989, 33, 1291-1297.
36. Bray, M.; Driscoll, J.; Huggins, J. W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res. 2000, 45, 135-147.
37. Bray, M.; Raymond, J. L.; Geisbert, T.; Baker, R. O. 3-Deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res. 2002, 55, 151-159.
38. Carter, W. A.; De Clercq, E. Viral infection and host defense (many aspects of viral infection and recovery can be explained by the modulatory role of double-stranded RNA). Science 1974, 186, 1172-1178.
39. Barrientos, L. G.; O'Keefe, B. R.; Bray, M.; Sanchez, A.; Gronenborn, A. M.; Boyd, M. R. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003, 58, 47-56.
40. Balzarini, J.; Pannecouque, C.; De Clercq, E.; Pavlov, A. Y.; Printsevskaya, S. S.; Miroshnikova, O. V.; Reznikova, M. I.; Preobrazhenskaya, M. N. Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J. Med. Chem. 2003, 46, 2755-2764.
41. Balzarini, J.; Schols, D.; Neyts, J.; Van Damme, E.; Peumans, W.; De Clercq, E. α-(1-3)-and α-(1-6)-D-Mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob. Agents Che-mother. 1991, 35, 410-416.
42. Krug, R. M. The potential use of influenza virus as an agent for bioterrorism. Antiviral Res. 2003, 57, 147-150.
43. Koopmans, M.; Wilbrink, B.; Conyn, M.; Natrop, G.; van der Nat, H.; Vennema, H.; Meijer, A.; van Steenbergen, J.; Fouchier, R.; Osterhaus, A.; Bosman, A. Transmission of H7N7 avian influenza A virus to human being during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004, 363, 587-593.
44. Fouchier, R. A. M.; Schneeberger, P. M.; Rozendaal, F. W.; Broekman, J. M.; Kemink, S. A. G.; Munster, V.; Kuiken, T.; Rimmelzwaan, G. F.; Schutten, M.; van Doornum, G. J. J.; Koch, G.; Bosman, A.; Koopmans, M.; Osterhaus, A. D. M. E. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. USA 2004, 101, 1356-1361.
45. von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Van Phan, T.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-423.
46. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischof-berger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Sevens, R. C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119, 681-690.
47. Lam, S.-K. Nipah virus-a potential agent of bioterrorism? Antiviral Res. 2003, 57, 113-119.
48. van den Hoogen, B. G.; de Jong, J. C.; Groen, J.; Kuiken, T.; de Groot, R.; Fouchier, R. A. M.; Osterhaus, A. D. M. E. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 2001, 7, 729-724.
49. van den Hoogen, B. G.; van Doornum, G. J. J.; Fockens, J. C.; Cornelissen, J. J.; Beyer, W. E. P.; de Groot, R.; Osterhaus, A. D. M. E.; Fouchier, R. A. M. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J. Infect. Dis. 2003, 188, 1571-1577.
50. Peret, T. C. T.; Boivin, G.; Li, Y.; Couillard, M.; Humphrey, C.; Osterhaus, A. D. M. E.; Erdman, D. D.; Anderson, L. J. Characterization of human metapneumoviruses isolated from patients in North America. J. Infect. Dis. 2002, 185, 1660-1663.
51. Cane, P. A.; van den Hoogen, B. G.; Chakrabarti, S.; Fegan, C. D.; Osterhaus, A.D.M.E. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant. 2003, 31, 309-310.
52. Zambon, M. C.; Stockton, J. D.; Clewley, J. P.; Fleming, D. M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001, 358, 1410-1416.
53. Huntley, C. C.; Weiss, W. J.; Gazumyan, A.; Buklan, A.; Feld, B.; Hu, W.; Jones, T. R.; Murphy, T.; Nikitenko, A. A.; O'Hara, B.; Prince, G.; Quartuccio, S.; Raifeld, Y. E.; Wyde, P.; O'Connell, J. F. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob. Agents Chemother. 2002, 46, 841-847.
54. Cianci, C.; Yu, K.-L.; Combrink, K.; Sin, N.; Pearce, B.; Wang, A.; Civiello, R.; Voss, S.; Luo, G.; Kadow, K.; Genovesi, E. V.; Venables, B.; Gulgeze, H.; Trehan, A.; James, J.; Lamb, L.; Medina, I.; Roach, J.; Yang, Z.; Zadjura, L.; Colonno, R.; Clark, J.; Meanwell, N.; Krystal, M. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 2004, 48, 413-422.
55. th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A60, no. 82.
56. Peiris, J. S.; Lai, S. T.; Poon, L. L.; Guan, Y.; Yam, L. Y.; Lim, W.; Nicholls, J.; Yee, W. K.; Yan, W. W.; Cheung, M. T.; Cheng, V. C.; Chan, K. H.; Tsang, D. N.; Yung, R. W.; Ng, T. K.; Yuen, K. Y.; SARS Study Group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361, 1319-1325.
57. Lee, N.; Hui, D.; Wu, A.; Chan, P.; Cameron, P.; Joynt, G. M.; Ahuja, A.; Yung, M. Y.; Leung, C. B.; To, K. F.; Lui, S. F.; Szeto, C. C.; Chung, S.; Sung, J. J. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003, 348, 1986-1994.
58. Ksiazek, T. G.; Erdman, D.; Goldsmith, C. S.; Zaki, S. R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J. A.; Lim, W.; Rollin, P. E.; Dowell, S. F.; Ling, A. E.; Humphrey, C. D.; Shieh, W. J.; Guarner, J.; Paddock, C. D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J. Y.; Cox, N.; Hughes, J. M.; LeDuc, J. W.; Bellini, W. J.; Anderson, L. J.; SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1953-1966.
59. Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H. R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R. A.; Berger, A.; Burguiere, A. M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J. C.; Muller, S.; Rickerts, V.; Sturmer, M.; Vieth, S.; Klenk, H. D.; Osterhaus, A. D.; Schmitz, H.; Doerr, H. W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1967-1976.
60. Kuiken, T.; Fouchier, R. A. M.; Schutten, M.; Rimmelzwaan, G. F.; van Amerongen, G.; van Riel, D.; Laman, J. D.; de Jong, T.; van Doornum, G.; Lim, W.; Ling, A. E.; Chan, P. K. S.; Tam, J. S.; Zambon, M. C.; Gopal, R.; Drosten, C.; van der Werf, S.; Escriou, N.; Manuguerra, J.-C.; Stöhr, K.; Peiris, J. S. M.; Osterhaus, A. D. M. E. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003, 362, 263-270.
61. Fouchier, R. A.; Kuiken, T.; Schutten, M.; van Amerongen, G.; van Doornum, G. J. J.; van den Hoogen, B.; Peiris, M.; Lim, W.; Stöhr, K.; Osterhaus, A. D. M. E. Koch's postulates fulfilled for SARS virus. Nature 2003, 423, 240.
62. Stadler, K.; Masignani, V.; Eickmann, M.; Becker, S.; Abrignani, S.; Klenk, H.-D.; Rappuoli, R. SARS-beginning to understand a new virus. Nat. Rev. Microbiol. 2003, 1, 209-218.
63. Thiel, V.; Ivanov, K. A.; Putics, A.; Hertzig, T.; Schelle, B.; Bayer, S.; Weissbrich, B.; Snijder, E. J.; Rabenau, H.; Doerr, H. W.; Gorbalenya, A. E.; Ziebuhr, J. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 2003, 84, 2305-2315.
64. Li, W.; Moore, M. J.; Vasilieva, N.; Sui, J.; Wong, S. K.; Berne, M. A.; Somasundaran, M.; Sullivan, J. L.; Luzuriaga, K.; Greenough, T. C.; Choe, H.; Farzan, M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450-454.
65. Wong, S. K.; Li, W.; Moore, M. J.; Choe, H.; Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 2004, 279, 3197-3201.
66. Sui, J.; Li, W.; Murakami, A.; Tamin, A.; Matthews, L. J.; Wong, S. K.; Moore, M. J.; St. Clair Tallarico, A.; Olurinde, M.; Choe, H.; Anderson, L. J.; Bellini, W. J.; Farzan, M.; Marasco, W. A. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 2536-2541.
67. Towler, P.; Staker, B.; Prasad, S. G.; Menon, S.; Tang, J.; Parsons, T.; Ryan, D.; Fisher, M.; Williams, D.; Dales, N. A.; Patane, M. A.; Pantoliano, M. W. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 2004, 279, 17996-18007.
68. pro) structure: basis for design of anti-SARS drugs. Science 2003, 300, 1763-1767.
69. Chou, K.-C.; Wei, D. Q.; Zhong, W.-Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun. 2003, 308, 148-151.
70. Yang, H.; Yang, M.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; Gao, G. F.; Anand, K.; Bartlam, M.; Hilgenfeld, R.; Rao, Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190-13195.
71. 0 viral helicases. J. Biol. Chem. 2003, 278, 39578-39582.
72. Xu, X.; Liu, Y.; Weiss, S.; Arnold, E.; Sarafianos, S. G.; Ding, J. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res. 2003, 31, 7117-7130.
73. 4-hydroxycytidine. Antiviral Chem. Chemother. 2004, 15, 15-22.
74. Balzarini, J.; Keyaerts, E.; Vijgen, L.; De Clercq, E.; Printsevskaya, S. S.; Preobrazhenskaya, M.; Van Ranst, M. Inhibitory activity of vancomycin, eremomycin and teicoplanin aglycon derivatives against feline and human (i.e., SARS) coronaviruses. Abstracts of the 17th International Conference on Antiviral Research, Tucson, Arizona, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A59, no. 78.
75. Balzarini, J.; Vijgen, L.; Keyaerts, E.; Van Damme, E.; Peumans, W.; De Clercq, E.; Egberink, H.; Van Ranst, M. Mannose-specific plant lectins are potent inhibitors of coronavirus infection including the virus causing SARS. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A76, no. 122.
76. Vijgen, L.; Keyaerts, E.; Van Damme, E.; Peumans, W.; De Clercq, E.; Balzarini, J.; Van Ranst, M. Antiviral effect of plant compounds of the Alliaceae family against the SARS coronavirus. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A76, no. 123.
77. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H. W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003, 361, 2045-2046.
78. He, M.-L.; Zheng, B.; Peng, Y.; Peiris, J. S. M.; Poon, L. L. M.; Yuen, K.Y.; Lin, M. C. M.; Kung, H.-F.; Guan, Y. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA. 2003, 290, 2665-2666.
79. Neuman, B.; Stein, D.; Kroeker, A.; Kim, A.; Paulino, A.; Abma, J.; Bestwick, R.; Moulton, H.; Iversen, P.; Buchmeier, M. Rational mechanistic design of antisense morpholino oligomers to inhibit SARS coronavirus proliferation and growth. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Late Breakers, p. 11, LB-2.
80. Babcock, G. J.; Greenough, T. C.; Hernandez, H. J.; Thomas, W. D.; Lowy, I.; Graziano, R.; Finberg, R.; Subbarao, K.; Roberts, A.; Vogel, L.; Somasundaran, M.; Luzuriaga, K.; Ambrosino, D. M.; Sullivan, J. L. Human monoclonal antibodies against S glycoprotein neutralize SARS coronavirus (CoV) in mice. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Late Beakers, p. 12, LB-3.
81. Marti, J. F. B.; Jimenez, J. L.; Munoz-Fernandez, M. A. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Med. Sci. Monit. 2003, 9, SR41-SR46.
82. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H. W. Treatment of SARS with human interferons. Lancet 2003; 362, 293-294.
83. Tan, E. L. C.; Ooi, E. E.; Lin, C.-Y.; Tan, H. C.; Ling, A. E.; Lim, B.; Stanton, L. W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infect. Dis. 2004, 10, 581-586.
84. Dianzani, F.; Scagnolari, C.; Vincenzi, E.; Bellomi, F.; Clementi, M.; Antonelli, G. Antiviral action of interferons on human coronavirus. Abstracts of the 17th International Conference on Antiviral Research, Tucson, AZ, USA, 2-6 May 2004. Antiviral Res. 2004, 62, A87, no. 152.
85. Haagmans, B. L.; Kuiken, T.; Martina, B. E.; Fouchier, R. A. M.; Rimmelzwaan, G. F.; van Amerongen, G.; van Riel, D.; de Jong, T.; Itamura, S.; Chan, K.-H.; Tashiro, M.; Osterhaus, A. D. M. E. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 2004, 10, 290-293.
86. Fouchier, R. A. M.; Hartwig, N. G.; Bestebroer, T. M.; Niemeyer, B.; de Jong, J. C.; Simon, J. H. Osterhaus, A. D. M. E. A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6212-6216.
87. Van der Hoek, L.; Pyrc, K.; Jebbink, M. F.; Vermeulen-Oost, W.; Berkhout, R. J. M.; Wolthers, K. C.; Wertheim-Van Dillen, P. M.; Kaandorp, J.; Spaargaren, J.; Berkhout, B. Identification of a new human coronavirus. Nat. Med. 2004, 10, 368-373.